摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

盐酸槟榔碱 | 61-94-9

中文名称
盐酸槟榔碱
中文别名
檳榔鹼酸甲酯鹽酸鹽
英文名称
Arecoline hydrochloride
英文别名
arecoline hydrochloride;1-methyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester; hydrochloride;1-Methyl-1,2,5,6-tetrahydro-pyridin-3-carbonsaeure-methylester; Hydrochlorid;methyl 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride;hydron;methyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate;chloride
盐酸槟榔碱化学式
CAS
61-94-9
化学式
C8H13NO2*ClH
mdl
——
分子量
191.658
InChiKey
LQSWCSYIDIBGRR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    157-158 °C(Solv: ethyl ether (60-29-7))

计算性质

  • 辛醇/水分配系数(LogP):
    0.84
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933399090
  • 储存条件:
    库房应保持通风、低温和干燥,并与食品原料分开存放。

SDS

SDS:5e0abdc0064ba0a8919efc8a27ad3dde
查看

制备方法与用途

类别:有毒物品
毒性分级:高毒
急性毒性:

  • 腹腔注射 - 小鼠 LD50: 154 毫克/公斤
  • 静脉注射 - 小鼠 LD50: 32 毫克/公斤

可燃性危险特性:可燃;燃烧时会产生有毒的氮氧化物和氯化氢烟雾
储运特性:应存放在库房中,通风、低温且干燥,并与食品原料分开存放
灭火剂:干粉、泡沫、沙土、二氧化碳或雾状

反应信息

点击查看最新优质反应信息

文献信息

  • 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds
    申请人:Brion Jean-Daniel
    公开号:US20090258883A1
    公开(公告)日:2009-10-15
    Compounds of formula (I): wherein: A represents a divalent radical: wherein: Z represents an oxygen atom or a sulphur atom, R 6 represents a hydrogen atom, an alkyl, alkenyl, arylalkyl or polyhaloalkyl group or a substituted, linear or branched alkyl chain, represents a single bond or a double bond, R 1 , R 2 , R 3 and R 4 represent a hydrogen or halogen atom, an alkyl, alkoxy, hydroxy, cyano, nitro, polyhaloalkyl or optionally substituted amino group, or a linear or branched alkyl chain substituted by one or more groups, R 5 represents a hydrogen atom or an alkyl, aminoalkyl or hydroxyalkyl group, X and Y represent a hydrogen atom or an alkyl group, R a , R b , R c and R d represent a hydrogen or halogen atom, an alkyl, hydroxy, alkoxy, cyano, nitro, polyhaloalkyl, optionally substituted amino group, or a substituted, linear or branched alkyl chain, R e represents a hydrogen atom or an alkyl, arylalkyl or alkenyl group or a substituted, linear or branched alkyl chain, their enantiomers, diastereoisomers, and N-oxides, and also addition salts thereof with a pharmaceutically acceptable acid or base.
    化合物的化学式(I): 其中: A代表二价基团: 其中: Z代表氧原子或原子, R 6 代表氢原子,烷基,烯烃基,芳基烷基或多卤代烷基基团或一个取代的,线性或支链烷基链, 代表单键或双键, R 1 ,R 2 ,R 3 和R 4 代表氢或卤素原子, 烷基,烷氧基,羟基,基,硝基,多卤代烷基或可选择取代的基团,或一个线性或支链烷基链,被一个或多个基团取代, R 5 代表氢原子或烷基,基烷基或羟基烷基, X和Y代表氢原子或烷基, R a ,R b ,R c 和R d 代表氢或卤素原子,烷基,羟基,烷氧基,基,硝基,多卤代烷基,可选择取代的基团,或一个取代的,线性或支链烷基链, R e 代表氢原子或烷基,芳基烷基或烯烃基或一个取代的,线性或支链烷基链, 它们的对映体,非对映异构体和N-氧化物,以及与药学上可接受的酸或碱形成的加合物盐。
  • USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES
    申请人:Le Ridant Alain
    公开号:US20090298813A1
    公开(公告)日:2009-12-03
    Use of neuroprotective compounds in obtaining medicaments intended for the curative treatment of neurodegenerative disease and/or the prevention of the appearance of disorders ensuing from those diseases.
    使用神经保护化合物来获取用于治疗神经退行性疾病和/或预防由这些疾病引起的随之而来的疾病的药物。
  • Collection of traceable compounds and uses thereof
    申请人:Centre National de la Recherche Scientifique (CNRS)
    公开号:US07745413B2
    公开(公告)日:2010-06-29
    The use of a collection of compounds of general formula (I), wherein: n is 0 or 1; p represents an integer between 1 and 6; r represents an integer between 1 and 12; R1 and R′1 represent in particular a hydrogen atom; R2 represents an amino acid side chain or an amino acid derivative; R3 represents a group derived from a carboxylic acid, bearing a basic entity; R4 represents in particular an alkyl group containing 1 to 10 carbon atoms; and A represents a hydrogen atom, a protecting group or a tracing group, in particular a fluorophor, a coloring agent or a quencher, for determining, through binding studies, ligands of receptors whose ligand is unknown or whose ligand useful for carrying out specific affinity binding assays is unknown.
    使用一系列通式(I)的化合物,其中:n为0或1;p表示1到6之间的整数;r表示1到12之间的整数;R1和R′1特别表示氢原子;R2表示氨基酸侧链或氨基酸生物;R3表示从羧酸衍生的带有碱性实体的基团;R4特别表示含有1到10个碳原子的烷基基团;A表示氢原子、保护基或示踪基,特别是荧光染料着色剂或猝灭剂,用于通过结合研究确定受体配体配体是未知的或用于进行特定亲和结合测定的配体是未知的。
  • Collection of Traceable Compounds and Uses Thereof
    申请人:Hibert Marcel Francois Louis
    公开号:US20080176763A1
    公开(公告)日:2008-07-24
    The invention concerns the use of a collection of compounds of general formula (I), wherein: n is 0 or 1; p represents an integer between 1 and 6; r represents an integer between 1 and 12; R 1 and R′ 1 represent in particular a hydrogen atom; R 2 represents an amino acid side chain or an amino acid derivative; R 3 represents a group derived from a carboxylic acid, bearing a basic entity; R 4 represents in particular an alkyl group containing 1 to 10 carbon atoms; and A represents a hydrogen atom, a protecting group or a tracing group, in particular a fluorophor, a colouring agent or a quencher, for determining, through binding studies, ligands of receptors whose ligand is unknown or whose ligand useful for carrying out specific affinity binding assays is unknown.
    本发明涉及使用一系列化合物的方法,其通式为(I),其中:n为0或1;p表示1到6之间的整数;r表示1到12之间的整数;R1和R′1特别表示氢原子;R2表示氨基酸侧链或氨基酸生物;R3表示从羧酸衍生的带有碱性基团的基团;R4特别表示含有1到10个碳原子的烷基基团;A表示氢原子、保护基或示踪基,特别是荧光团、着色剂或淬灭剂,用于通过结合研究确定受体的配体,其配体未知或用于进行特定亲和结合测定的配体未知。
  • CYCLOALKENYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
    申请人:THE BOARD INSTITUTE, INC.
    公开号:US20150368221A1
    公开(公告)日:2015-12-24
    The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.
    本发明提供了公式(I)的化合物或其药学上可接受的盐、溶剂或前药,其中W、X、n、s、t和Ra如本文所述。本发明通常涉及组织脱乙酰化酶的选择性抑制剂以及制备和使用它们的方法。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台